Orticumab

Drug Profile

Orticumab

Alternative Names: Anti-oxLDL; BI-204; MLDL 1278A; RG 7418

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator BioInvent International
  • Developer BioInvent International; Genentech
  • Class Anti-inflammatories; Antibodies; Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 30 Jan 2013 Discontinued - Phase-I for Atherosclerosis in Denmark (IV)
  • 30 Jan 2013 Discontinued - Phase-I for Atherosclerosis in Denmark (SC)
  • 30 Jan 2013 Discontinued - Phase-I for Atherosclerosis in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top